Tocilizumab administration in patients with SARS-CoV-2 infection: Subcutaneous injection vs intravenous infusion.
作者信息
Shabani Minoosh, Shokouhi Shervin, Moradi Omid, Saffaei Ali, Sahraei Zahra
机构信息
Department of Infectious Diseases and Tropical Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
出版信息
J Med Virol. 2021 Jan;93(1):69-70. doi: 10.1002/jmv.26124. Epub 2020 Jun 19.
Abstract
摘要
相似文献
1
Tocilizumab administration in patients with SARS-CoV-2 infection: Subcutaneous injection vs intravenous infusion.
J Med Virol. 2021 Jan;93(1):69-70. doi: 10.1002/jmv.26124. Epub 2020 Jun 19.
2
Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies.
Int J Infect Dis. 2020 Dec;101:59-64. doi: 10.1016/j.ijid.2020.09.1447. Epub 2020 Sep 28.
3
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954.
4
An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic.
Rheumatology (Oxford). 2021 Feb 1;60(2):977-979. doi: 10.1093/rheumatology/keaa653.
5
Tocilizumab alleviates cytokine storm with acute respiratory distress syndrome in severe SARS-CoV-2 infection in Taiwan.
Intern Med J. 2021 Sep;51(9):1543-1544. doi: 10.1111/imj.15335.
6
Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
J Autoimmun. 2020 Nov;114:102512. doi: 10.1016/j.jaut.2020.102512. Epub 2020 Jul 3.
7
Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19.
JAMA Netw Open. 2022 Apr 1;5(4):e226920. doi: 10.1001/jamanetworkopen.2022.6920.
8
Tocilizumab prescribing criteria for COVID-19 patients.
Hum Vaccin Immunother. 2021 Apr 3;17(4):1128. doi: 10.1080/21645515.2020.1822137. Epub 2020 Oct 20.
9
Effect of subcutaneous vs. intravenous tocilizumab in patients with severe COVID-19: a systematic review.
Eur J Clin Pharmacol. 2024 Oct;80(10):1523-1530. doi: 10.1007/s00228-024-03719-0. Epub 2024 Jun 27.
10
Use of intravenous tocilizumab in pregnancy for severe coronavirus disease 2019 pneumonia: two case reports.
J Med Case Rep. 2021 Aug 7;15(1):426. doi: 10.1186/s13256-021-03010-1.
引用本文的文献
1
A meta-analysis of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatment for COVID-19 patients.
Ther Adv Chronic Dis. 2021 Aug 20;12:20406223211039699. doi: 10.1177/20406223211039699. eCollection 2021.
2
The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19).
Int J Mol Sci. 2020 Sep 3;21(17):6412. doi: 10.3390/ijms21176412.
3
Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
Int Immunopharmacol. 2020 Nov;88:106869. doi: 10.1016/j.intimp.2020.106869. Epub 2020 Aug 4.
本文引用的文献
1
Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia.
J Med Virol. 2021 Jan;93(1):32-34. doi: 10.1002/jmv.26016. Epub 2020 Sep 30.
2
Tocilizumab treatment in COVID-19: A single center experience.
J Med Virol. 2020 Jul;92(7):814-818. doi: 10.1002/jmv.25801. Epub 2020 Apr 15.
3
COVID-19: consider cytokine storm syndromes and immunosuppression.
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
4
Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).
Ann Rheum Dis. 2016 Jan;75(1):68-74. doi: 10.1136/annrheumdis-2015-207281. Epub 2015 Jun 8.
5
Drug absorption, distribution, metabolism and excretion considerations in critically ill adults.
Expert Opin Drug Metab Toxicol. 2013 Sep;9(9):1067-84. doi: 10.1517/17425255.2013.799137. Epub 2013 May 17.
6
Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects.
Int J Clin Pharmacol Ther. 2013 Jun;51(6):443-55. doi: 10.5414/CP201819.
Zotero 插件